Ventripoint Diagnostics Ltd. (TSX-V:VPT, OTC:VPTDF) announced that its strategic partner, Lishman Global Inc., has formally submitted the company’s VMS+™ 4.0 system to China’s National Medical Products Administration (NMPA) for regulatory approval. Lishman Global has qualified for the NMPA’s “green channel” pathway, an expedited review process designed to accelerate approval of innovative medical technologies that address significant clinical needs.
This submission marks a key step in Ventripoint’s global expansion strategy, targeting China, one of the world’s largest healthcare markets. Cardiovascular disease is the leading cause of mortality in China, affecting an estimated 330 million patients. Echocardiography is widely used due to its cost-effectiveness and portability, but variability in image interpretation and limited access to MRI have created demand for AI-driven tools like VMS+™ 4.0.
Ventripoint’s VMS+™ 4.0 uses proprietary Knowledge Based Reconstruction technology to provide MRI-equivalent volumetric measurements from standard 2D echocardiography. It enables clinicians to assess all four heart chambers with high accuracy, aiding in diagnosis and management of congenital heart defects, heart failure, pulmonary hypertension, cardiotoxicity, and valvular disease.
“We are excited to take this important step toward bringing VMS+™ 4.0 to the Chinese market,” said Paul Gibson, Chief Technology Officer of Lishman Global Inc. “Qualification for the NMPA’s green channel underscores the clinical relevance and innovation of VMS+™ 4.0 and provides a clear pathway to accelerated adoption. China’s scale, combined with its increasing focus on improving cardiovascular outcomes, makes it an ideal environment for this technology.”
“Hitting this regulatory milestone with Lishman Global is a key validation of both our technology and our international strategy,” said Hugh MacNaught, President and CEO of Ventripoint Diagnostics. “China is one of the most important cardiac care markets in the world. With the benefit of an expedited review pathway, we are well positioned to bring VMS+™ 4.0 to clinicians and patients more quickly.”
The green channel designation is expected to streamline the regulatory timeline, potentially reducing the time to market compared to standard approval processes. Ventripoint’s VMS+ products are already approved in the U.S., Europe, and Canada, and are compatible with all ultrasound systems. The company will provide further updates as the review progresses.
For more information, visit Ventripoint Diagnostics or the original release on NewMediaWire.
